Changes in national rates of psychiatric beds and incarceration in Central Eastern Europe and Central Asia from 1990-2019: A retrospective database analysis.

BACKGROUND: Numbers of psychiatric beds (general, forensic, and residential) and prison populations have been considered to be indicators of institutionalisation of people with mental illnesses. The present study aimed to assess changes of those indicators across Central Eastern Europe and Central Asia (CEECA) over the last three decades to capture how care has developed during that historical period. METHODS: We retrospectively obtained data on numbers of psychiatric beds and prison populations from 30 countries in CEECA between 1990 and 2019. We calculated the median of the percent changes between the first and last available data points for all CEECA and for groups of countries based on former political alliances and income levels. FINDINGS: Primary national data were retrieved from 25 out of 30 countries. Data from international registries were used for the remaining five countries. For all of CEECA, the median decrease of the general psychiatric bed rates was 33•8% between 1990 and 2019. Median increases were observed for forensic psychiatric beds (24•7%), residential facility beds (12•0%), and for prison populations (36•0%). Greater reductions of rates of psychiatric beds were observed in countries with lower per capita income as well as in countries that were formerly part of the Soviet Union. Seventeen out of 30 countries showed inverse trends for general psychiatric beds and prison populations over time, indicating a possible shift of institutionalisation towards correctional settings. INTERPRETATION: Most countries had decreased rates of general psychiatric beds, while there was an increase of forensic capacities. There was an increase in incarceration rates in a majority of countries. The large variation of changes underlines the need for policies that are informed by data and by comparisons across countries. FUNDING: Agencia Nacional de Investigación y Desarrollo in Chile, grant scheme FONDECYT Regular, grant number 1190613.

Different serum BDNF levels in depression: results from BDNF studies in FYR Macedonia and Bulgaria.

BACKGROUND: A growing body of evidence shows that brain-derived neurotrophic factor (BDNF) plays a role in depressive disorder. Serum BDNF levels are lower in depressed patients and they increase after a long course of antidepressant treatment. Our study aims to test the effect of antidepressant treatment on serum BDNF levels in patients with a depressive episode, after they have achieved remission in two studies in Macedonia and Bulgaria. SUBJECTS AND METHODS: In the Macedonian study 23 patients were included (11 female, 12 male) diagnosed with a first depressive episode according to ICD-10, as well as 23 control subjects age- and sex-matched without a history of psychiatric disorder. In the Bulgarian study 10 female patients with depression and 10 control subjects were included. We have applied the Hamilton Depression Rating Scale (HDRS) to assess depression severity. Blood samples were collected before antidepressive treatment and after remission was achieved (decrease to 7 points or less on HDRS). RESULTS: In the Macedonian study, mean serum BDNF level at baseline was 13.15±6.75 ng/ml and the mean HDRS score was 28.52±4.02. Untreated depressed patients showed significantly lower serum BDNF levels compared to the control group (25.95±9.17 ng/ml). After remission was achieved, the mean serum BDNF level was 24.73±11.80 ng/ml whereas the mean HDRS score was 7.04±3.15. After 8 weeks of treatment there was no statistically significant difference in the serum BDNF levels between the two groups. In the Bulgarian study, baseline mean serum BDNF levels were 26.84±8.66 ng/ml, after 3 weeks treatment and remission was achieved mean serum BDNF levels were 30.33±9.25 ng/ml and in the control group mean serum BDNF levels were 25.04±2.88 ng/ml. Integrated results showed baseline mean serum BDNF levels of 17.30±9.66 ng/ml, after achieved remission 26.43±11.25 ng/ml and in the control group mean serum BDNF levels of 25.68±7.76 ng/ml. CONCLUSION: The Bulgarian results showed no statistical difference between the depressed group and controls. The Integrated results and the Macedonian study supported previous findings of low BDNF levels in untreated depressive patients compared to healthy controls, and that those levels increase after antidepressant treatment. These results may suggest that low serum levels of BDNF are a state abnormality that is evident during depression and normalizes during remission.

Forensic psychiatry in some Balkan countries.

PURPOSE OF REVIEW: In Balkan countries, as in all Europe, forensic psychiatry as a subspecialty between psychiatry and legal medicine, an interface between mental health and the law, is focused on assessment and treatment of people with mental disorder who show antisocial or violent behavior. Thus, the authors thought that to show the actual situation of forensic psychiatry in their countries would be more interesting than only to review some articles published in these last 2 years in this part of the world. RECENT FINDINGS: The article also includes some review about forensic psychiatry in prison in Bulgaria, Serbia and Russia and about a recent book published in Bulgaria. SUMMARY: After a brief history of forensic psychiatry in some Balkan countries, the authors describe the services, the high and medium secure units found in forensic hospitals or in general psychiatry hospitals, which are still limited, where mentally disordered offenders are treated. Because of our society's values, individual freedom and civil liberties, questions about the right to treatment (or the right to refuse treatment), involuntary hospitalization, and other legal and ethical issues have no easy answers. Ethical questions remain in dispute, like patient's needs vs. social needs and human rights, legality vs. morality.The quality standards must be improved, especially those concerning elementary care needs and quality of life of forensic psychiatry patients (accommodation, food, sheltered housing, sheltered work places and community involvement). Ways will be found to protect human rights and avoid any abuse of psychiatry.